The rise of CAR-T cell therapies has led to the need for advances in cell culture media to meet the varying demands of cell therapy production (consistency, optimal phenotype, etc.). Valuable resources are spent optimizing media formulations (e.g., serum free or chemically defined) that are often prohibitively expensive or yield suboptimal growth or function. There are challenges with current serum options. FBS is not a viable option for translational cell work. Human AB serum suffers from lack of consistency or availability. Cell therapy manufacturers need reagents that allow for them to proliferate and sustain life saving cells in a safe and effective manner.
A Novel Media Supplementation Strategy for Improved T Cell Culture and Preservation of Naivety
30 Sep 2018